#1 Clinical Trials Search in Europe

Emibetuzumab

Emibetuzumab, also known as LY2875358, is an investigational drug being studied in clinical trials for various types of cancer, including non-small cell lung cancer (NSCLC) and advanced cancers. These trials aim to evaluate the safety and efficacy of Emibetuzumab, both as a standalone treatment and in combination with other drugs such as Erlotinib and Ramucirumab. The studies focus on patients with specific biomarkers or those who have developed resistance to previous treatments, offering hope for new therapeutic options in cancer care.

Table of Contents

What is Emibetuzumab?

Emibetuzumab, also known by its research name LY2875358, is an investigational drug being studied for its potential in treating various types of cancer[1][2]. It is a type of medication called a monoclonal antibody, which means it’s designed to target specific proteins in the body that are involved in cancer growth.

What Conditions Does Emibetuzumab Treat?

Emibetuzumab is being investigated for its effectiveness in treating several types of advanced cancers, including:

  • Non-Small Cell Lung Cancer (NSCLC): This is a type of lung cancer that accounts for about 80-85% of all lung cancers[1][2].
  • Gastric Adenocarcinoma: A type of stomach cancer that starts in the glandular cells of the stomach lining[2].
  • Gastroesophageal Junction Adenocarcinoma: Cancer that occurs where the esophagus (food pipe) meets the stomach[2].
  • Hepatocellular Cancer: The most common type of liver cancer[2].
  • Renal Cell Carcinoma: The most common type of kidney cancer in adults[2].

It’s important to note that Emibetuzumab is still in the research phase, and its effectiveness for these conditions is still being evaluated.

How is Emibetuzumab Administered?

Emibetuzumab is administered intravenously (IV), which means it’s given directly into the bloodstream through a vein. The dosing schedule can vary depending on the specific clinical trial, but typically it’s given as follows:

  • A dose of 750 milligrams (mg) or 2000 mg, given as a 1.5-hour infusion
  • Usually administered on Days 1 and 15 of a 28-day cycle[1][2]

The exact dosage and schedule may be adjusted based on how well the patient tolerates the treatment and how effective it is.

Combination Therapy with Emibetuzumab

Researchers are studying Emibetuzumab both as a standalone treatment and in combination with other cancer drugs. Some combinations being investigated include:

  • Emibetuzumab with Erlotinib: Erlotinib is an oral medication used to treat certain types of lung cancer. This combination is being studied in patients with NSCLC who have developed resistance to Erlotinib alone[1].
  • Emibetuzumab with Ramucirumab: Ramucirumab (also known as LY3009806 or IMC-1121B) is another intravenous drug used to treat various types of cancer. This combination is being studied for its potential in treating advanced cancers[2].

How is the Efficacy of Emibetuzumab Measured?

Researchers use several methods to evaluate how well Emibetuzumab works. These include:

  • Overall Response Rate (ORR): This measures the percentage of patients whose cancer shrinks or disappears after treatment[1][2].
  • Progression-Free Survival (PFS): This measures how long patients live without their cancer getting worse[1][2].
  • Disease Control Rate (DCR): This includes patients whose cancer shrinks or remains stable[1][2].
  • Overall Survival (OS): This measures how long patients live after starting treatment[1].

Researchers also use various imaging techniques and standardized criteria (like RECIST v1.1) to measure changes in tumor size and assess the drug’s effectiveness.

Potential Side Effects and Safety Considerations

As with any medication, Emibetuzumab may cause side effects. Researchers carefully monitor patients for what they call “Dose-Limiting Toxicities” (DLTs), which are side effects severe enough to limit the dose that can be given. Some potential side effects being monitored include:

  • Nausea, vomiting, diarrhea, or constipation
  • Skin rash
  • High blood pressure (hypertension)
  • Changes in blood cell counts
  • Fever with low white blood cell count (febrile neutropenia)[2]

It’s important to note that not all patients will experience these side effects, and the research is ongoing to fully understand the safety profile of Emibetuzumab.

Ongoing Research and Future Prospects

Emibetuzumab is still in the clinical trial phase, which means it’s not yet approved for general use outside of research studies. Ongoing research aims to:

  • Determine the most effective and safe dosage
  • Evaluate its effectiveness in different types of cancer
  • Assess its performance both alone and in combination with other cancer treatments
  • Understand how the body processes the drug (pharmacokinetics)
  • Monitor for the development of antibodies against the drug, which could affect its effectiveness[1][2]

The results of these studies will help determine whether Emibetuzumab could become a new treatment option for patients with various types of cancer in the future.

Aspect Details
Drug Name Emibetuzumab (LY2875358)
Administration Intravenous (IV)
Cancer Types Studied Non-Small Cell Lung Cancer (NSCLC), Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Hepatocellular Cancer, Renal Cell Carcinoma, Advanced Cancer
Combination Therapies Erlotinib, Ramucirumab
Key Outcome Measures Overall Response Rate (ORR), Progression-Free Survival (PFS), Disease Control Rate (DCR), Safety and Tolerability
Dosage in Trials Varies, examples include 750 mg or 2000 mg every 28 days
Patient Selection Some trials focus on MET biomarker-positive patients or those with acquired resistance to previous treatments

FAQ

  • What is Emibetuzumab? Emibetuzumab, also known as LY2875358, is an investigational drug being studied for the treatment of various types of cancer, including non-small cell lung cancer (NSCLC) and advanced cancers. It is typically administered intravenously (IV) in clinical trials.
  • What types of cancer is Emibetuzumab being studied for? Emibetuzumab is being studied for several types of cancer, including non-small cell lung cancer (NSCLC), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, hepatocellular cancer, renal cell carcinoma, and other advanced cancers.
  • How is Emibetuzumab administered in clinical trials? In the clinical trials, Emibetuzumab is typically administered intravenously (IV). The dosage and frequency can vary, but in some trials, it is given as a 1.5-hour IV infusion on Days 1 and 15 of a 28-day cycle.
  • Is Emibetuzumab being studied alone or in combination with other drugs? Emibetuzumab is being studied both as a standalone treatment and in combination with other drugs. For example, it has been studied in combination with Erlotinib for NSCLC and with Ramucirumab for various advanced cancers.
  • What are the main goals of the clinical trials involving Emibetuzumab? The main goals of the clinical trials include evaluating the safety and efficacy of Emibetuzumab, determining appropriate dosages, assessing its effect on tumor size and progression, measuring overall survival rates, and studying how well it works in combination with other cancer treatments.

Ongoing Clinical Trials on Emibetuzumab

  • Study of Erlotinib and LY2875358 for Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Mutations After Initial Erlotinib Treatment

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Spain

Glossary

  • Emibetuzumab: An investigational drug, also known as LY2875358, being studied for the treatment of various types of cancer. It is typically administered intravenously in clinical trials.
  • Non-Small Cell Lung Cancer (NSCLC): A type of lung cancer that is the subject of some Emibetuzumab clinical trials. It is one of the most common types of lung cancer.
  • MET biomarker: A specific biological marker that is used to identify patients who might be suitable for certain treatments, including some Emibetuzumab trials.
  • Erlotinib: A cancer medication that is sometimes studied in combination with Emibetuzumab. It is typically administered orally.
  • Ramucirumab: Another cancer drug that is being studied in combination with Emibetuzumab for various advanced cancers. It is administered intravenously.
  • Intravenous (IV): A method of administering medication directly into a vein. Emibetuzumab is typically given this way in clinical trials.
  • Overall Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment. This is a key measure in many cancer clinical trials.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse. This is an important outcome measure in cancer trials.
  • RECIST: Response Evaluation Criteria in Solid Tumors. This is a standard way to measure how well a cancer patient responds to treatment.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted. This is often studied in clinical trials.

References

  1. https://clinicaltrials.gov/study/NCT01900652
  2. https://clinicaltrials.gov/study/NCT02082210